Garching / Munich, Germany, June 13, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it will provide further analysis from its recently completed Phase 3 COMPETE trial in an oral presentation and Satellite Symposium at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, held from June 21 – June 24, 2025 in New Orleans, Louisiana. Details of the Oral PresentationThe data will be presented by Dr. Thomas A. Hope, MD, Chief of Nuclear Medicine at the San Francisco VA Medical Center and Vice Chair of Clinical Operations and Strategy in the Department of Radiology at UCSF in an oral presentation titled, “Predicting the [177Lu]Lu-edotreotide uptake in tumors using pre-therapeutic Ga-68 PET/CT imaging”, on Sunday, June 22 in the Neuroendocrine – Oncology Clinical Diagnosis and Therapy session from 3:30 – 4:45 pm CDT. The presentation will provide an analysis on the 177Lu-edotreotide tumor uptake and its predictability based on pre-therapeutic SSTR PET/CT imaging and other factors.